Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. There are no changes to the study content or user-facing information on the page.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. This appears to be a minor software version update with no visible changes to the study information.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision: v3.4.1 was added (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision: v3.4.1 appears on the page, replacing v3.4.0; there are no visible changes to trial content or details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check60 days agoChange DetectedShow glossary option added to the page interface. Minor text updates include capitalization changes to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data,' and the revision version updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.